Stellar Zogenix Phase III Epilepsy Data Lift ZX008's Competitive Position
Company is planning to file in the second half with two pivotal studies, but says it is "worth exploring" with the US FDA whether data from the first study could support an application.
You may also be interested in...
Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.
Beyond Epidiolex for severe epilepsy, cannabinoid candidates are in development for a range of diseases, including acute pain, graft-versus-host disease, scleroderma, schizophrenia, pain and substance use disorder.
The latest drug development news and highlights from our US FDA Performance Tracker.